...
首页> 外文期刊>Journal of Radiation Research: Official Organ of the Japan Radiation Research Society >Dosimetric research into target regions and organs at risk in three-dimensional intracavitary brachytherapy techniques for Chinese patients with cervical carcinoma
【24h】

Dosimetric research into target regions and organs at risk in three-dimensional intracavitary brachytherapy techniques for Chinese patients with cervical carcinoma

机译:宫颈癌患者三维颈椎近距离放射治疗技术的靶区域和器官的靶区域和器官。

获取原文
获取原文并翻译 | 示例
           

摘要

The present study aimed to compare the dosages of target regions and organs at risk (OARs) in 3D intracavitary brachytherapy (ICBT) and conventional 2D ICBT for Chinese patients with cervical carcinoma. ICBT was performed in a total of 66 patients with Stage IB to IVA cervical carcinoma who had not received surgery but who had received whole-pelvic external-beam radiotherapy (EBRT). Plans for the 3D-ICBT and the conventional 2D-ICBT were individually designed for every patient. The dosages differences between the target regions and the OARs in patients with each of the various stages of cervical carcinoma were compared between the two ICBT plans. There was no significant difference in the dose at Point A between the two ICBT plans. However, the CTVhr-D-90, CTVhr-D-100 and CTVir-D-90 in 3D-ICBT were much higher than in 2D-ICBT, especially in Stage IIB (P < 0.05). As compared with conventional 2D-ICBT, the dosages of D-ICRU and D-2.0cm3 in the rectum/bladder, and D-2.0cm3 in the sigmoid/small bowel were decreased significantly in 3D-ICBT (P < 0.05). For patients with Stage IIA, IIB and IIIB, the D-2.0cm3 in the rectum/bladder was significantly reduced in 3D-ICBT (P < 0.05). It was demonstrated that, in Chinese patients, 3D-ICBT for cervical carcinoma could optimize the target coverage and reduce the dosages to the OARs compared with conventional 2D-ICBT.
机译:本研究旨在将靶区域和器官的剂量与风险(OAR)的剂量进行比较3D腔内近距离放射治疗(ICBT)和常规2D ICBT用于中国宫颈癌患者。 ICBT总共进行了66名患有IVA宫颈癌的阶段IB患者,尚未接受手术,但曾接受过全盆外梁放射治疗(EBRT)。 3D-ICBT的计划和传统的2D-ICBT为每个患者单独设计。在两个ICBT计划之间比较了宫颈癌各个阶段各个阶段的患者靶区域和OAR之间的剂量差异。两种ICBT计划之间的剂量没有显着差异。然而,3D-ICBT中的CTVHR-D-90,CTVHR-D-100和CTVIR-D-90远高于2D-ICBT,特别是在阶段IIB中(P <0.05)。与常规的2D-ICBT相比,3D-ICBT中的直肠/膀胱中的D-ICRU和D-2.0cm3和Sigmoid /小肠中的D-2.0cm3的剂量显着下降(P <0.05)。对于IIA阶段,IIB和IIIB患者,3D-ICBT中的直肠/膀胱中的D-2.0CM3显着降低(P <0.05)。据证明,在中国患者中,与常规2D-ICBT相比,宫颈癌的3D-ICBT可优化目标覆盖率并减少剂量给桨的剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号